Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Oncologist. 2021 Sep 28. doi: 10.1002/onco.13964. Online ahead of print.ABSTRACTThe disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and persistent over time, with the largest disparities appearing among women with hormone receptor-positive (HR+) cancers. The racial gap in breast cancer survival first emerged in the 1980s, a time of significantmen treatment advances in early-stage breast cancer, including the introduction of adjuvant endocrine therapy. Since that time, the gap has continued to widen despite steady advances in treatment and survival of breast cancer overal...
Source: The Oncologist - September 28, 2021 Category: Cancer & Oncology Authors: Katherine E Reeder-Hayes Melissa A Troester Stephanie B Wheeler Source Type: research

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
Oncologist. 2021 Sep 21. doi: 10.1002/onco.13983. Online ahead of print.NO ABSTRACTPMID:34546620 | DOI:10.1002/onco.13983 (Source: The Oncologist)
Source: The Oncologist - September 21, 2021 Category: Cancer & Oncology Authors: Aaron P Mitchell Akriti Mishra Pranam Dey Michael A Curry Niti U Trivedi Michael Haddadin Mohammed W Rahman Aaron N Winn Stacie B Dusetzina Peter B Bach Source Type: research

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
Oncologist. 2021 Sep 21. doi: 10.1002/onco.13983. Online ahead of print.NO ABSTRACTPMID:34546620 | DOI:10.1002/onco.13983 (Source: The Oncologist)
Source: The Oncologist - September 21, 2021 Category: Cancer & Oncology Authors: Aaron P Mitchell Akriti Mishra Pranam Dey Michael A Curry Niti U Trivedi Michael Haddadin Mohammed W Rahman Aaron N Winn Stacie B Dusetzina Peter B Bach Source Type: research

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
Oncologist. 2021 Sep 21. doi: 10.1002/onco.13983. Online ahead of print.NO ABSTRACTPMID:34546620 | DOI:10.1002/onco.13983 (Source: The Oncologist)
Source: The Oncologist - September 21, 2021 Category: Cancer & Oncology Authors: Aaron P Mitchell Akriti Mishra Pranam Dey Michael A Curry Niti U Trivedi Michael Haddadin Mohammed W Rahman Aaron N Winn Stacie B Dusetzina Peter B Bach Source Type: research

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
Oncologist. 2021 Sep 21. doi: 10.1002/onco.13983. Online ahead of print.NO ABSTRACTPMID:34546620 | DOI:10.1002/onco.13983 (Source: The Oncologist)
Source: The Oncologist - September 21, 2021 Category: Cancer & Oncology Authors: Aaron P Mitchell Akriti Mishra Pranam Dey Michael A Curry Niti U Trivedi Michael Haddadin Mohammed W Rahman Aaron N Winn Stacie B Dusetzina Peter B Bach Source Type: research

Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines
Oncologist. 2021 Sep 21. doi: 10.1002/onco.13983. Online ahead of print.NO ABSTRACTPMID:34546620 | DOI:10.1002/onco.13983 (Source: The Oncologist)
Source: The Oncologist - September 21, 2021 Category: Cancer & Oncology Authors: Aaron P Mitchell Akriti Mishra Pranam Dey Michael A Curry Niti U Trivedi Michael Haddadin Mohammed W Rahman Aaron N Winn Stacie B Dusetzina Peter B Bach Source Type: research

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial
CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET ...
Source: The Oncologist - September 15, 2021 Category: Cancer & Oncology Authors: Anna Minchom Aaron C Tan Erminia Massarelli Vivek Subbiah Valentina Boni Bruce Robinson Lori J Wirth Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Caroline E McCoach Source Type: research

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial
CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET ...
Source: The Oncologist - September 15, 2021 Category: Cancer & Oncology Authors: Anna Minchom Aaron C Tan Erminia Massarelli Vivek Subbiah Valentina Boni Bruce Robinson Lori J Wirth Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Caroline E McCoach Source Type: research

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial
CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET ...
Source: The Oncologist - September 15, 2021 Category: Cancer & Oncology Authors: Anna Minchom Aaron C Tan Erminia Massarelli Vivek Subbiah Valentina Boni Bruce Robinson Lori J Wirth Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Caroline E McCoach Source Type: research

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial
CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET ...
Source: The Oncologist - September 15, 2021 Category: Cancer & Oncology Authors: Anna Minchom Aaron C Tan Erminia Massarelli Vivek Subbiah Valentina Boni Bruce Robinson Lori J Wirth Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Caroline E McCoach Source Type: research

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial
CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET ...
Source: The Oncologist - September 15, 2021 Category: Cancer & Oncology Authors: Anna Minchom Aaron C Tan Erminia Massarelli Vivek Subbiah Valentina Boni Bruce Robinson Lori J Wirth Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Caroline E McCoach Source Type: research

Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial
CONCLUSION: In this interim analysis, the majority of patients with RET fusion-positive NSCLC remained stable or improved on all QLQ-C30 subscales at each study visit, demonstrating the favorable HRQoL as measured by the QLQ-C30 during treatment with selpercatinib.IMPLICATIONS FOR PRACTICE: Patients with non-small cell lung cancer (NSCLC) generally experience greater symptom burden and lower health-related quality of life (HRQoL) as disease progresses. In a phase 1/2 trial, improvements in HRQoL were observed in over 60% of patients with advanced RET fusion-positive NSCLC who received selpercatinib, a highly selective RET ...
Source: The Oncologist - September 15, 2021 Category: Cancer & Oncology Authors: Anna Minchom Aaron C Tan Erminia Massarelli Vivek Subbiah Valentina Boni Bruce Robinson Lori J Wirth Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Caroline E McCoach Source Type: research

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO-001Trial
CONCLUSION: These interim results demonstrate that patients with RET-mutant MTC improved/remained stable on all domains of HRQoL during treatment with selpercatinib. Future analyses will be conducted as the data mature.IMPLICATIONS FOR PRACTICE: Patients with metastatic medullary thyroid cancer (MTC) frequently experience disease-related diarrhea that can significantly impair daily living. Standards of care for the treatment of MTC include RET-targeted therapies as well as multikinase inhibitors (MKIs). Over 40% of patients with RET-mutant MTC who received selpercatinib, a highly selective RET inhibitor, reported clinical ...
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Lori J Wirth Bruce Robinson Valentina Boni Daniel S W Tan Caroline McCoach Erminia Massarelli Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Vivek Subbiah Source Type: research

Increased Risk for Ipsilateral Breast Tumor Recurrence in Invasive Lobular Carcinoma after Accelerated Partial Breast Irradiation Brachytherapy
CONCLUSIONS: These results show that APBI is an effective treatment for patients with invasive breast cancer. Expansion of the current eligibility criteria should be considered, though prospective validation is needed. Caution is required when considering APBI for patients with ILC.IMPLICATIONS FOR PRACTICE: In a large retrospective review of 946 patients with early breast cancer treated with partial mastectomy and APBI intracavitary brachytherapy, we demonstrate durable local control. Patients deemed unsuitable or high risk by the American Brachytherapy Society, American Society of Therapeutic Radiation Oncology, and Euro...
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Matthew N Mills Nicholas W Russo Matthew Fahey Ronica H Nanda Sunny Raiker Jessica Jastrzebski Lisa L Stout Jason P Wilson Taghrid A Altoos Kathleen G Allen Peter W Blumencranz Roberto Diaz Source Type: research

Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
The objectives of the study were: 1) to confirm if symptoms of CINV led to lower QoL during AC; 2) to evaluate the pattern of changes in patients' QoL during multiple cycles of AC; and 3) to assess if the QoL in an earlier cycle affected the QOL in subsequent cycles of AC.METHODS: This is a secondary pooled data analysis that included 303 Chinese breast cancer patients who received 1177 cycles of adjuvant AC in three prospective antiemetic studies. QoL data was based on Functional Living Index- Emesis (FLIE) scored over three to four AC cycles. CINV symptoms assessed included 'no significant nausea' (NSN), 'significant nau...
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Winnie Yeo Frankie K F Mo Christopher C H Yip Victoria A Yeo Leung Li Thomas K H Lau Kwai T Lai Vicky T C Chan Kwan H Wong Elizabeth Pang Maggie Cheung Vivian Chan Carol C H Kwok Joyce J S Suen Alex Molassiotis Source Type: research

BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report
This report describes a case of ROS1-rearranged NSCLC who acquired a BRAF V600E and lost the ROS1 fusion after crizotinib failure. The case was subsequently treated with dabrafenib and trametinib combination and achieved a partial response lasting for more than 6 months. This is the first case reporting the treatment with dabrafenib and trametinib may serve as an effective option for later-line treatment for patients harboring resistant BRAF V600E.PMID:34516041 | DOI:10.1002/onco.13979 (Source: The Oncologist)
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Juan Li Qifeng Wang Jun Ge Yuke Tian Wenxiu Yao Source Type: research

In Reply
Oncologist. 2021 Sep 13. doi: 10.1002/onco.13982. Online ahead of print.NO ABSTRACTPMID:34516697 | DOI:10.1002/onco.13982 (Source: The Oncologist)
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Robert W Corty Source Type: research

Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD-1/PD-L1 Blockade Therapies
The objective response rate (ORR) and DCR in PD-L1-high patients were higher than those in the other patients (32.44% vs 13.64%, P=0.018 and 75.68% vs 40.91%, P
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Zhaoli Tan Chunyan Yue Shoujian Ji Chuanhua Zhao Ru Jia Yun Zhang Rongrui Liu Da Li Qian Yu Ping Li Zhiyuan Hu Yanlian Yang Jianming Xu Source Type: research

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO-001Trial
CONCLUSION: These interim results demonstrate that patients with RET-mutant MTC improved/remained stable on all domains of HRQoL during treatment with selpercatinib. Future analyses will be conducted as the data mature.IMPLICATIONS FOR PRACTICE: Patients with metastatic medullary thyroid cancer (MTC) frequently experience disease-related diarrhea that can significantly impair daily living. Standards of care for the treatment of MTC include RET-targeted therapies as well as multikinase inhibitors (MKIs). Over 40% of patients with RET-mutant MTC who received selpercatinib, a highly selective RET inhibitor, reported clinical ...
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Lori J Wirth Bruce Robinson Valentina Boni Daniel S W Tan Caroline McCoach Erminia Massarelli Lisa M Hess Min-Hua Jen Jennifer Kherani Elizabeth Olek Vivek Subbiah Source Type: research

Increased Risk for Ipsilateral Breast Tumor Recurrence in Invasive Lobular Carcinoma after Accelerated Partial Breast Irradiation Brachytherapy
CONCLUSIONS: These results show that APBI is an effective treatment for patients with invasive breast cancer. Expansion of the current eligibility criteria should be considered, though prospective validation is needed. Caution is required when considering APBI for patients with ILC.IMPLICATIONS FOR PRACTICE: In a large retrospective review of 946 patients with early breast cancer treated with partial mastectomy and APBI intracavitary brachytherapy, we demonstrate durable local control. Patients deemed unsuitable or high risk by the American Brachytherapy Society, American Society of Therapeutic Radiation Oncology, and Euro...
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Matthew N Mills Nicholas W Russo Matthew Fahey Ronica H Nanda Sunny Raiker Jessica Jastrzebski Lisa L Stout Jason P Wilson Taghrid A Altoos Kathleen G Allen Peter W Blumencranz Roberto Diaz Source Type: research

Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
The objectives of the study were: 1) to confirm if symptoms of CINV led to lower QoL during AC; 2) to evaluate the pattern of changes in patients' QoL during multiple cycles of AC; and 3) to assess if the QoL in an earlier cycle affected the QOL in subsequent cycles of AC.METHODS: This is a secondary pooled data analysis that included 303 Chinese breast cancer patients who received 1177 cycles of adjuvant AC in three prospective antiemetic studies. QoL data was based on Functional Living Index- Emesis (FLIE) scored over three to four AC cycles. CINV symptoms assessed included 'no significant nausea' (NSN), 'significant nau...
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Winnie Yeo Frankie K F Mo Christopher C H Yip Victoria A Yeo Leung Li Thomas K H Lau Kwai T Lai Vicky T C Chan Kwan H Wong Elizabeth Pang Maggie Cheung Vivian Chan Carol C H Kwok Joyce J S Suen Alex Molassiotis Source Type: research

BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report
This report describes a case of ROS1-rearranged NSCLC who acquired a BRAF V600E and lost the ROS1 fusion after crizotinib failure. The case was subsequently treated with dabrafenib and trametinib combination and achieved a partial response lasting for more than 6 months. This is the first case reporting the treatment with dabrafenib and trametinib may serve as an effective option for later-line treatment for patients harboring resistant BRAF V600E.PMID:34516041 | DOI:10.1002/onco.13979 (Source: The Oncologist)
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Juan Li Qifeng Wang Jun Ge Yuke Tian Wenxiu Yao Source Type: research

In Reply
Oncologist. 2021 Sep 13. doi: 10.1002/onco.13982. Online ahead of print.NO ABSTRACTPMID:34516697 | DOI:10.1002/onco.13982 (Source: The Oncologist)
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Robert W Corty Source Type: research

Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD-1/PD-L1 Blockade Therapies
The objective response rate (ORR) and DCR in PD-L1-high patients were higher than those in the other patients (32.44% vs 13.64%, P=0.018 and 75.68% vs 40.91%, P
Source: The Oncologist - September 13, 2021 Category: Cancer & Oncology Authors: Zhaoli Tan Chunyan Yue Shoujian Ji Chuanhua Zhao Ru Jia Yun Zhang Rongrui Liu Da Li Qian Yu Ping Li Zhiyuan Hu Yanlian Yang Jianming Xu Source Type: research

Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion
CONCLUSION: The findings from the three experiments in this study suggest that disclosures have the potential to increase relevant knowledge, but more research is needed to establish best practice recommendations for using disclosures to convey contextual information relevant for interpreting data displays in promotional communications.IMPLICATIONS FOR PRACTICE: Our manuscript reports the results from three large, online experimental studies that address a growing concern that drug companies often share favorable clinical trial results with physicians in promotional materials that lack important context for physicians to i...
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Vanessa Boudewyns Amie C O'Donoghue Ryan S Paquin Kathryn J Aikin Kate Ferriola-Bruckenstein Victoria M Scott Source Type: research

Changes in cancer patients' and caregivers' disease perceptions while receiving early palliative care: a qualitative and quantitative analysis
Oncologist. 2021 Sep 12. doi: 10.1002/onco.13974. Online ahead of print.ABSTRACTBACKGROUND: Little is known about underlying mechanisms through which early palliative care (EPC) improves multiple outcomes in cancer patients and their caregivers. The aims of this study were to qualitatively and quantitatively analyze patients' and caregivers' thoughts, emotional and cognitive perceptions about the disease prior and during the EPC intervention, and in the end of life, following the exposure to EPC.MATERIALS AND METHODS: Seventy-seven advanced cancer patients and 48 caregivers from two cancer centers participated in semi-stru...
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Eleonora Borelli Sarah Bigi Leonardo Potenza Sonia Eliardo Fabrizio Artioli Claudia Mucciarini Luca Cottafavi Katia Cagossi Giorgia Razzini Massimiliano Cruciani Alessandra Pietramaggiori Valeria Fantuzzi Laura Lombardo Umberto Ferrari Vittorio Ganfi Faus Source Type: research

The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
CONCLUSION: In older patients with advanced cancer, frailty is associated with poorer emotional health, which indicates a need for an integrated care approach to treating these patients.IMPLICATIONS FOR PRACTICE: A relationship exists between frailty and poor emotional health in older adults with advanced cancer. Identifying areas of frailty can prompt screening for emotional health and guide delivery of appropriate interventions. Alternatively, attention to emotional health may also improve frailty.PMID:34510642 | DOI:10.1002/onco.13975 (Source: The Oncologist)
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Nikesha Gilmore Lee Kehoe Jessica Bauer Huiwen Xu Bianca Hall Megan Wells Lianlian Lei Eva Culakova Marie Flannery Valerie Aarne Grossman Ronak Amir Sardari Himal Subramanya Sindhuja Kadambi Elizabeth Belcher Jared Kettinger Mark A O'Rourke Elie G Dib Nic Source Type: research

Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress
CONCLUSION: While substantial proportions of advanced lung cancer patients had inaccurate prognostic understanding from the time of diagnosis over time, patients with consistently accurate prognostic understanding experienced greater psychological burden. Our findings highlight the importance of continuous psychological care and support for patients that understand their severe prognosis accurately.IMPLICATIONS FOR PRACTICE: This study demonstrated that approximately 20% of patients with advanced lung cancer had inaccurate understanding about their prognosis not only at the time of diagnosis but also at the later time poin...
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Daisuke Arai Takashi Sato Ichiro Nakachi Daisuke Fujisawa Mari Takeuchi Yasunori Sato Ichiro Kawada Hiroyuki Yasuda Shinnosuke Ikemura Hideki Terai Shigenari Nukaga Takashi Inoue Morio Nakamura Yoshitaka Oyamada Takeshi Terashima Koichi Sayama Fumitake Sa Source Type: research

Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion
CONCLUSION: The findings from the three experiments in this study suggest that disclosures have the potential to increase relevant knowledge, but more research is needed to establish best practice recommendations for using disclosures to convey contextual information relevant for interpreting data displays in promotional communications.IMPLICATIONS FOR PRACTICE: Our manuscript reports the results from three large, online experimental studies that address a growing concern that drug companies often share favorable clinical trial results with physicians in promotional materials that lack important context for physicians to i...
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Vanessa Boudewyns Amie C O'Donoghue Ryan S Paquin Kathryn J Aikin Kate Ferriola-Bruckenstein Victoria M Scott Source Type: research

Changes in cancer patients' and caregivers' disease perceptions while receiving early palliative care: a qualitative and quantitative analysis
Oncologist. 2021 Sep 12. doi: 10.1002/onco.13974. Online ahead of print.ABSTRACTBACKGROUND: Little is known about underlying mechanisms through which early palliative care (EPC) improves multiple outcomes in cancer patients and their caregivers. The aims of this study were to qualitatively and quantitatively analyze patients' and caregivers' thoughts, emotional and cognitive perceptions about the disease prior and during the EPC intervention, and in the end of life, following the exposure to EPC.MATERIALS AND METHODS: Seventy-seven advanced cancer patients and 48 caregivers from two cancer centers participated in semi-stru...
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Eleonora Borelli Sarah Bigi Leonardo Potenza Sonia Eliardo Fabrizio Artioli Claudia Mucciarini Luca Cottafavi Katia Cagossi Giorgia Razzini Massimiliano Cruciani Alessandra Pietramaggiori Valeria Fantuzzi Laura Lombardo Umberto Ferrari Vittorio Ganfi Faus Source Type: research

The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
CONCLUSION: In older patients with advanced cancer, frailty is associated with poorer emotional health, which indicates a need for an integrated care approach to treating these patients.IMPLICATIONS FOR PRACTICE: A relationship exists between frailty and poor emotional health in older adults with advanced cancer. Identifying areas of frailty can prompt screening for emotional health and guide delivery of appropriate interventions. Alternatively, attention to emotional health may also improve frailty.PMID:34510642 | DOI:10.1002/onco.13975 (Source: The Oncologist)
Source: The Oncologist - September 12, 2021 Category: Cancer & Oncology Authors: Nikesha Gilmore Lee Kehoe Jessica Bauer Huiwen Xu Bianca Hall Megan Wells Lianlian Lei Eva Culakova Marie Flannery Valerie Aarne Grossman Ronak Amir Sardari Himal Subramanya Sindhuja Kadambi Elizabeth Belcher Jared Kettinger Mark A O'Rourke Elie G Dib Nic Source Type: research